Login to Your Account



Albany Molecular Licenses CNS Compounds To BMS

By Jennifer Boggs


Tuesday, October 25, 2005
In its largest deal since 1995, Albany Molecular Research Inc. exclusively licensed a portfolio of biogenic amine reuptake inhibitors to Bristol-Myers Squibb Co. for the development of drugs to treat depression and other central nervous system disorders. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription